Alume Biosciences delivers positive topline results for three pivotal trials of Bevonescein, advancing toward NDA submission with US FDA in 2H 2026 Even with meticulous technique, surgeons are limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results